Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 10.
doi: 10.1097/QAD.0000000000004401. Online ahead of print.

Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial

Marissa R Diggs  1 , Sarah M Chu  1 , Kathleen V Fitch  1 , Maxine Olefsky  2 , Maya G Watanabe  2 , Kristine M Erlandson  3 , Alex B Lu  1 , Gerald S Bloomfield  4 , Judith S Currier  5 , Adrian Curran  6 , Allison R Eckard  7 , Graham H R Smith  8 , Craig A Sponseller  9 , Carl J Fichtenbaum  10 , Carlos D Malvestutto  11 , Judith A Aberg  12 , Borek Foldyna  13 , Jana Taron  13   14 , Julia Karady  13 , Markella V Zanni  1 , Pamela S Douglas  15 , Heather J Ribaudo  2 , Michael T Lu  13 , Steven K Grinspoon  1
Affiliations

Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial

Marissa R Diggs et al. AIDS. .

Abstract

Background: There is limited evidence concerning the relationship between cardiometabolic characteristics and health-related quality of life (HRQoL), and potential effects of statin therapy among people with HIV (PWH).

Methods: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) enrolled PWH aged 40-75 years on antiretroviral therapy (ART) with low-to-moderate ASCVD risk. Coronary computed tomography angiography assessed coronary plaque among a subset of participants in the REPRIEVE Mechanistic Substudy at baseline and 24 months. The Short Form-36-Item Health Survey Version 2 was collected at baseline, and physical (PCS) and mental (MCS) component summary scores were determined. We explored the relationship of PCS and MCS with cardiometabolic characteristics, coronary atherosclerosis, and assessed change in score by treatment group (pitavastatin vs. placebo).

Results: Of 733 participants, median age was 51 years, 84% were male, 34% were Black non-Hispanic, and median years diagnosed with HIV was 15. At baseline, for participants randomized to pitavastatin vs. placebo the median PCS was 54.5 (Q1,Q3: 46.9, 57.7) vs. 54.1 (47.5, 58.0), and the median MCS was 52.9 (44.1, 57.6) vs. 52.8 (44.0, 57.9). In fully adjusted analyses, older age, Black non-Hispanic race/ethnicity, ART regimen class, elevated BMI, and cigarette smoking were associated with lower PCS. No clear trends were apparent with MCS. Between baseline and month 24, declines in PCS and MCS were minimal with no apparent difference by treatment group.

Conclusions: Among this cohort of ART-treated PWH, baseline cardiometabolic risk factors were associated with worse self-reported physical HRQoL, with no apparent effect of statin therapy.

Trial registration: REPRIEVE; NCT02344290; https://clinicaltrials.gov/study/NCT02344290.

Keywords: HIV; atherosclerotic cardiovascular disease; cardiovascular disease; coronary CTA; health-related quality of life; statins.

PubMed Disclaimer

Associated data

LinkOut - more resources